Yıl: 2015 Cilt: 11 Sayı: 2 Sayfa Aralığı: 59 - 66 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way

Öz:
Breast carcinoma comprises a group of diseases with specific clinical, histopathologic and molecular properties. Traditional classification use morphology to divide tumors into separate categories with differing behavior and prognosis. However, there are limitations of traditional classification systems, and new molecular methods are expected to improve classification systems. Molecular subtypes of breast carcinomas have been characterized in the last 11 years, and have been studied extensively. Much of the information accumulated in recent years, and molecular taxonomy seems to be still developing and undergoing change. The main question is whether new molecular techniques such as gene expression profiling will be accepted as gold standard in determining breast cancer subtypes, and whether molecular classification is useful in specific subtypes of breast cancer as it is in ductal carcinoma (nonspecific type). In addition, critical review of the literature reveals major problems such as poor definition, lack of reproducibility and lack of quality control in current molecular techniques and classifications. Therefore, current molecular approaches are not yet used in routine clinical practice and treatment guidance since they are immature and can even lead to incorrect assessment.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer statistics. CA Cancer J Clin 2011; 61:69-90. (PMID: 21296855) [CrossRef]
  • 2. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin, 2006; 56:37-47. (PMID: 16449185)
  • 3. Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R. Invasive breast carcinomas. In: Tavassoli FA, Devilee P, editors. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003. p 13-19.
  • 4. Weigelt, B. & Reis-Filho, J. S. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6:718- 730. (PMID: 19942925) [CrossRef]
  • 5. Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W.Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999; 189:521-526. (PMID: 10629552) [CrossRef]
  • 6. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010; 12:207. (PMID: 20804570)
  • 7. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010; 120:293-308. (PMID: 20107892) [CrossRef]
  • 8. Denoix PF. Nomenclature classification des cancers [in French]. Bull Inst Nat Hyg (Paris) 1952; 7:743-748.
  • 9. International Union Against Cancer. TNM Classification of Malignant Tumours. Geneva, Switzerland: International Union Against Cancer; 1968
  • 10. Veronesia U, Vialeb G, Rotmensza N, Goldhirscha. A Rethinking TNM: Breast cancer TNM classification for treatment decision-making and research The Breast 2006; 15:3-8. (PMID: 16473737) [CrossRef]
  • 11. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat, 1992; 22:207- 19. (PMID: 1391987) [CrossRef]
  • 12. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J J Clin Oncol 2001; 19:980-991. (PMID: 11181660)
  • 13. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16:1569-1583. (PMID: 16148022) [CrossRef]
  • 14. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406:747-752. (PMID: 10963602) [CrossRef]
  • 15. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874. (PMID: 11553815) [CrossRef]
  • 16. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D.Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 1:8418-8423. (PMID: 12829800) [CrossRef]
  • 17. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS.Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-1167. (PMID: 19204204) [CrossRef]
  • 18. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96-107. (PMID: 16643655) [CrossRef]
  • 19. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 2006; 11:868-877. (PMID: 16951390) [CrossRef]
  • 20. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Prac Oncol 2006; 3:621-632. (PMID: 17080180) [CrossRef]
  • 21. Kapp AV, Jeffrey SS, Langerod A, Borresen-Dale AL, Han W, Noh DY, Bukholm IR, Nicolau M, Brown PO, Tibshirani R. Discovery and validation of breast cancer subtypes. BMC Genomics 2006; 7:231. (PMID: 16965636) [CrossRef]
  • 22. Mackay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A’Hern R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Microarray-based class discovery for molecular classification of breast cancer: analysis of interob-server agreement. J Natl Cancer Inst 2011; 103:662-673. (PMID: 21421860) [CrossRef]
  • 23. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012; 104:311-325. (PMID: 22262870) [CrossRef]
  • 24. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012; 135:301-306. (PMID: 22752290) [CrossRef]
  • 25. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277. (PMID: 20498394) [CrossRef]
  • 26. Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 2010; 119:685-699. (PMID: 20012355) [CrossRef]
  • 27. Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010; 28:1813-1820. (PMID: 20231686) [CrossRef]
  • 28. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2010;102(10):1-8. (PMID: 20825420) [CrossRef]
  • 29. Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J.A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the downmodulation of the estrogen receptor in HER-2 positive breast cancers. Cancer Res. 2010; 70:8537-8546. (PMID: 20978202) [CrossRef]
  • 30. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A.Quantitation of p95HER2 in parafin sections by sections using a p95-spesific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010: 16:4226-4235. (PMID: 20664024) [CrossRef]
  • 31. Marianna Sasso, Francesca Bianchi, Valentina Ciravolo, Elda Tagliabue, Manuela Campiglio HER2 splice variants and their relevance in breast cancer. Journal of Nucleic Acids Investigation 2011; volume 2:e9. [CrossRef]
  • 32. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14:1368-1376. (PMID: 18316557) [CrossRef]
  • 33. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TOKi67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736-750. (PMID: 19436038) [CrossRef]
  • 34. Modified from Schnitt SJ. Will molecular classification replace traditional breast pathology? Int J Surg Pathol 2010; 18:162S-166S. (PMID: 20484283) [CrossRef]
  • 35. Correa Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol 2009; 17:285-302. (PMID: 19103611) [CrossRef]
  • 36. Cummings MC, Chambers R, Simpson PT, Lakhani SR. Molecular classification of breast cancer: is it time to pack up our microscopes? Pathology. January 2011; 43, pp. 1-8. (PMID: 21240058) [CrossRef]
  • 37. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2:367-76. (PMID: 12450792) [CrossRef]
  • 38. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009; 106:18740-18744. (PMID: 19841262) [CrossRef]
  • 39. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van’t Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216:141-150. (PMID: 18720457) [CrossRef]
  • 40. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008; 44:73-83. (PMID: 18035533) [CrossRef]
  • 41. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008; 26:3006- 3014. (PMID: 18458044) [CrossRef]
  • 42. Viale G, Rotmensz N, Maisonneuve P, Orvieto E, Maiorano E, Galimberti V, Luini A, Colleoni M, Goldhirsch A, Coates AS. Lack of prognostic significance of ‘classic’ lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 2009; 117:211-214. (PMID: 18629634) [CrossRef]
  • 43. Gruel N, Lucchesi C, Raynal V, Rodrigues MJ, Pierron G, Goudefroye R, Cottu P, Reyal F, Sastre-Garau X, Fourquet A, Delattre O, VincentSalomon A.Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer 2010; 46:2399-2407. (PMID: 20570624) [CrossRef]
  • 44. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993; 114:637-641. (PMID: 8211676)
  • 45. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 1991; 48:28-33. (PMID: 1653879) [CrossRef]
  • 46. Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA.A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 1984;
  • 50:23-30. (PMID: 6331484) [CrossRef] 47. Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin Diagn Pathol 2010; 27:49-61. (PMID: 20306830) [CrossRef]
  • 48. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992; 23:655-662. (PMID: 1592388) [CrossRef]
  • 49. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992; 23:1167-1171. (PMID: 1398644) [CrossRef]
  • 50. Buchanan CL, Flynn LW, Murray MP, Darvishian F, Cranor ML, Fey JV, King TA, Tan LK, Sclafani LM. Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol 2008; 98:314-317. (PMID: 18668643) [CrossRef]
  • 51. Vargas AC, Lakhani SR, Simpson PT. Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. Future Oncol 20095:233-243. (PMID: 19284381) [CrossRef]
  • 52. Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Dexter T, Jones A, Reid L, Da Silva L, Shin SJ, Hardisson D, Ashworth A, Schmitt FC, Palacios J, Lakhani SR. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008; 215:231-244 . (PMID: 18473330) [CrossRef]
  • 53. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP Clinical, histopathologic, and biologic features of pleomorphic lobular (ductallobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 2002; 15:1044-1050. (PMID: 12379750) [CrossRef]
  • 54. Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, Clarke C, Lakhani SR, Simpson PT. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008; 32:773-783. (PMID: 18379416) [CrossRef]
  • 55. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010; 57:171-192. (PMID: 20500230) [CrossRef]
  • 56. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO.High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007; 31:417- 426. (PMID: 17325484) [CrossRef]
  • 57. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP, Hanby A, Pinder SE, Lee AH, Humphreys S, Ellis IO, Lakhani SR. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005; 29:734- 746. (PMID: 15897740) [CrossRef]
  • 58. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. Adv Anat Pathol 2003; 10:113-24. (PMID: 12717115) [CrossRef]
  • 59. Gruel N, Lucchesi C, Raynal V, Rodrigues MJ, Pierron G, Goudefroye R, Cottu P, Reyal F, Sastre-Garau X, Fourquet A, Delattre O, VincentSalomon A. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer 2010; 46:2399-407. (PMID: 20570624 ) [CrossRef]
  • 60. Lopez-Garcia MA, Geyer FC, Natrajan R, Kreike B, Mackay A, Grigoriadis A, Reis-Filho JS, Weigelt B. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol 2010; 222:64- 75. (PMID: 20593406) [CrossRef]
  • 61. Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, Kreike B, Reis-Filho JS. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010; 220:45-57. (PMID: 19877120) [CrossRef]
  • 62. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing Ecadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001; 92:404-408. (PMID: 1129107) [CrossRef]
  • 63. Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, Reis-Filho JS, Ellis IO. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2010; 34:1472-1479. (PMID: 20871222) [CrossRef]
  • 64. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70. (PMID:23000897) [CrossRef]
APA ÖZKAVRUK ELİYATKIN N, YALÇIN E, ZENGEL B, Aktas S, vardar e (2015). Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. , 59 - 66.
Chicago ÖZKAVRUK ELİYATKIN NUKET,YALÇIN Evrim,ZENGEL Baha,Aktas Safiye,vardar enver Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. (2015): 59 - 66.
MLA ÖZKAVRUK ELİYATKIN NUKET,YALÇIN Evrim,ZENGEL Baha,Aktas Safiye,vardar enver Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. , 2015, ss.59 - 66.
AMA ÖZKAVRUK ELİYATKIN N,YALÇIN E,ZENGEL B,Aktas S,vardar e Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. . 2015; 59 - 66.
Vancouver ÖZKAVRUK ELİYATKIN N,YALÇIN E,ZENGEL B,Aktas S,vardar e Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. . 2015; 59 - 66.
IEEE ÖZKAVRUK ELİYATKIN N,YALÇIN E,ZENGEL B,Aktas S,vardar e "Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way." , ss.59 - 66, 2015.
ISNAD ÖZKAVRUK ELİYATKIN, NUKET vd. "Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way". (2015), 59-66.
APA ÖZKAVRUK ELİYATKIN N, YALÇIN E, ZENGEL B, Aktas S, vardar e (2015). Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. The Journal of Breast Health, 11(2), 59 - 66.
Chicago ÖZKAVRUK ELİYATKIN NUKET,YALÇIN Evrim,ZENGEL Baha,Aktas Safiye,vardar enver Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. The Journal of Breast Health 11, no.2 (2015): 59 - 66.
MLA ÖZKAVRUK ELİYATKIN NUKET,YALÇIN Evrim,ZENGEL Baha,Aktas Safiye,vardar enver Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. The Journal of Breast Health, vol.11, no.2, 2015, ss.59 - 66.
AMA ÖZKAVRUK ELİYATKIN N,YALÇIN E,ZENGEL B,Aktas S,vardar e Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. The Journal of Breast Health. 2015; 11(2): 59 - 66.
Vancouver ÖZKAVRUK ELİYATKIN N,YALÇIN E,ZENGEL B,Aktas S,vardar e Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. The Journal of Breast Health. 2015; 11(2): 59 - 66.
IEEE ÖZKAVRUK ELİYATKIN N,YALÇIN E,ZENGEL B,Aktas S,vardar e "Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way." The Journal of Breast Health, 11, ss.59 - 66, 2015.
ISNAD ÖZKAVRUK ELİYATKIN, NUKET vd. "Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way". The Journal of Breast Health 11/2 (2015), 59-66.